Theravance Biopharma Files 8-K on Financials
Ticker: TBPH · Form: 8-K · Filed: May 8, 2025 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Theravance Biopharma dropped an 8-K on May 8th detailing their financial condition. Check it out.
AI Summary
Theravance Biopharma, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company is incorporated in the Cayman Islands and its principal executive offices are located in South San Francisco, California.
Why It Matters
This filing provides an update on Theravance Biopharma's financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any immediate or significant new risks.
Key Players & Entities
- Theravance Biopharma, Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event Reported
- Cayman Islands (location) — State or Other Jurisdiction of Incorporation
- South San Francisco, CA (location) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on May 8, 2025.
Where is Theravance Biopharma, Inc. incorporated?
The company is incorporated in the Cayman Islands.
What is the principal business address for Theravance Biopharma, Inc.?
The principal executive offices are located at C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA 94080.
What is the SIC code for Theravance Biopharma, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Theravance Biopharma, Inc. (TBPH).